Furthermore, double IHC for IL-35 and Foxp3 revealed an increased co-localisation of these two markers in the TU region of patients with NSCLC as compared to their CTR region as well as compared to control patients (Fig. 3c, d). This evidence concerns the gene FOXP3 and non-small cell lung carcinoma.